Premium
Successful treatment of a child with late onset T‐cell post‐transplant lymphoproliferative disorder/lymphoma
Author(s) -
Williams Kirsten M.,
Higman Meghan A.,
Chen Allen R.,
Schwartz Cindy L.,
Wharam Moody,
Colombani Paul,
Arceci Robert J.
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21171
Subject(s) - medicine , alemtuzumab , fludarabine , hematopoietic stem cell transplantation , regimen , chemotherapy , oncology , lymphoma , cyclophosphamide , rituximab , cytarabine , thiotepa , transplantation , gastroenterology , immunology
We report a novel regimen for refractory post‐transplant T‐cell lymphoma (PTL). Our patient presented with non‐Epstein–Barr virus (EBV) related, T‐cell post‐transplant lymphoproliferative disease (PTLD) 3.5 years after liver transplantation. Initially diagnosed as polyclonal PTLD, the disease progressed to a monoclonal, T‐cell PTL that was refractory to several chemotherapy regimens but responded to a regimen consisting of fludarabine, cyclophosphamide, cytarabine, and alemtuzumab. Consolidation therapy included high‐dose chemotherapy, autologous hematopoietic stem cell rescue, and radiation therapy. She remains in remission 2.5 years later. T‐cell PTL is a rare disease with a poor prognosis; this regimen provides a novel, potentially curative approach for its treatment. Pediatr Blood Cancer 2008;50:667–670. © 2007 Wiley‐Liss, Inc.